{"id":3189,"date":"2025-05-20T14:13:11","date_gmt":"2025-05-20T12:13:11","guid":{"rendered":"https:\/\/wordpress-famicordcryobank-ch.empress.smarthost.pl\/?page_id=3189"},"modified":"2025-08-07T14:18:34","modified_gmt":"2025-08-07T12:18:34","slug":"riepilogo-pazienti-trattati","status":"publish","type":"page","link":"https:\/\/famicordcryobank.ch\/it\/summary-patients-treated","title":{"rendered":"Riepilogo pazienti trattati"},"content":{"rendered":"\n
\n\t
\n\t\t

\n\t\t\t\n\t\t\t\n\t\t\t\t\t\t\tSummary
patients treated<\/span>\n\t\t\t\t\t<\/h1>\n\t<\/div>\n\n\t
\n\t\t\n\t\t\t\n\t\t\t\t\n\t\t\t<\/mask>\n\t\t\t\n\t\t\t\t\n\t\t\t<\/g>\n\t\t\t\n\t\t<\/svg>\n\t<\/div>\n\n\t
\n\t\t\n\t\t\t\n\t\t\t\t\n\t\t\t<\/mask>\n\t\t\t\n\t\t\t\t\n\t\t\t<\/g>\n\t\t\t\n\t\t<\/svg>\n\t<\/div>\n<\/section>\n\n\n
\n
\n \n \n

\n\n Has anyone ever benefited from stem cell?\n\n <\/h2>\n\n \n
\n

For the first time, umbilical cord blood cells were successfully used in 1988 in France. Several years later, in 2007, this method was also introduced by FamiCord Group in Poland. So far, umbilical cord blood stem cells have been transplanted over 40,000 times worldwide, saving peoples\u2019 lives and health.<\/p>\n

FamiCord Group enables their clients innovative treatment with stem cells. Check the full list of patients, suffered from diverse disorders, who benefited from it.<\/p>\n\n <\/div>\n <\/div>\n<\/section>\n\n\n

\n
\n
\n \n

\n\n List of patients\n\n <\/h3>\n\n <\/header>\n <\/div>\n \n
\n
\n \n \n
\n\n \n \n \"\"\n\n <\/figure>\n\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
List of patients<\/caption>\n
No.<\/th>\n Source<\/th>\n Source type<\/th>\n Diagnosis<\/th>\n Medical sector<\/th>\n Year of application<\/th>\n Therapy<\/th>\n Country<\/th>\n Age of the recipient<\/th>\n <\/tr>\n <\/thead>\n
1<\/td>\n Cord Tissue<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 6<\/td>\n <\/tr>\n
2<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 6<\/td>\n <\/tr>\n
3<\/td>\n Cord Tissue<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 4<\/td>\n <\/tr>\n
4<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 6<\/td>\n <\/tr>\n
5<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Degenerative and Traumatic Cartilage<\/td>\n Orthopedy<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 50,3<\/td>\n <\/tr>\n
6<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Degenerative and Traumatic Cartilage<\/td>\n Orthopedy<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 49,5<\/td>\n <\/tr>\n
7<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Degenerative and Traumatic Cartilage<\/td>\n Orthopedy<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 58,11<\/td>\n <\/tr>\n
8<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Graft Versus Host Disease<\/td>\n Hematology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 7,7<\/td>\n <\/tr>\n
9<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Graft Versus Host Disease<\/td>\n Hematology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 15,7<\/td>\n <\/tr>\n
10<\/td>\n Cord Tissue<\/td>\n Allogeneic – Unrelated<\/td>\n Ovarian Dysfunction<\/td>\n Gynecology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 48,1<\/td>\n <\/tr>\n
11<\/td>\n Cord Tissue<\/td>\n Allogeneic – Related<\/td>\n Severe Pulmonary Hypertension +Mitral Regurgitation<\/td>\n Cardiovascular\/Pulmonary<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 2,6<\/td>\n <\/tr>\n
12<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 11<\/td>\n <\/tr>\n
13<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 10<\/td>\n <\/tr>\n
14<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 6<\/td>\n <\/tr>\n
15<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 4<\/td>\n <\/tr>\n
16<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Autism<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Romania<\/td>\n 5<\/td>\n <\/tr>\n
17<\/td>\n Cord Blood<\/td>\n Allogeneic<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 3,5<\/td>\n <\/tr>\n
18<\/td>\n Cord Blood<\/td>\n Allogeneic<\/td>\n Cerebral Palsy<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 7,7<\/td>\n <\/tr>\n
19<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n CP<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Hungary<\/td>\n 4<\/td>\n <\/tr>\n
20<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Pervasive Developmental Disorder<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 3,7<\/td>\n <\/tr>\n
21<\/td>\n Cord Blood<\/td>\n Autologous<\/td>\n Pervasive Developmental Disorder<\/td>\n Neurology<\/td>\n 2024<\/td>\n Experimental Therapy<\/td>\n Poland<\/td>\n 5,9<\/td>\n <\/tr>\n
22<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 69<\/td>\n <\/tr>\n
23<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 70<\/td>\n <\/tr>\n
24<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 75<\/td>\n <\/tr>\n
25<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 56<\/td>\n <\/tr>\n
26<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 23<\/td>\n <\/tr>\n
27<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 54<\/td>\n <\/tr>\n
28<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 69<\/td>\n <\/tr>\n
29<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 70<\/td>\n <\/tr>\n
30<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 65<\/td>\n <\/tr>\n
31<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 48<\/td>\n <\/tr>\n
32<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Acute Myeloid Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 72<\/td>\n <\/tr>\n
33<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Chronic Lymphocytic Leukemia Richter Transformation<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 55<\/td>\n <\/tr>\n
34<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Chronic Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 63<\/td>\n <\/tr>\n
35<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Follicular Lymphoma<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 48<\/td>\n <\/tr>\n
36<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 65<\/td>\n <\/tr>\n
37<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 58<\/td>\n <\/tr>\n
38<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 70<\/td>\n <\/tr>\n
39<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome – Refractory Cytopenia Of Childhood<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 14<\/td>\n <\/tr>\n
40<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome\/ Myeloproliferative Neoplasms<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 61<\/td>\n <\/tr>\n
41<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome-MPN<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 71<\/td>\n <\/tr>\n
42<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Myelofibrosis<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 68<\/td>\n <\/tr>\n
43<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Non-Hodgkin Lymphoma<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 64<\/td>\n <\/tr>\n
44<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Polycythemia Vera\/Myelofibrosis<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 74<\/td>\n <\/tr>\n
45<\/td>\n Bone Marrow Family<\/td>\n Allogeneic<\/td>\n Primary Myelofibrosis<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Germany<\/td>\n 62<\/td>\n <\/tr>\n
46<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 15<\/td>\n <\/tr>\n
47<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 8<\/td>\n <\/tr>\n
48<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 12<\/td>\n <\/tr>\n
49<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 8<\/td>\n <\/tr>\n
50<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 52<\/td>\n <\/tr>\n
51<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 57<\/td>\n <\/tr>\n
52<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 66<\/td>\n <\/tr>\n
53<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 5<\/td>\n <\/tr>\n
54<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 54<\/td>\n <\/tr>\n
55<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 56<\/td>\n <\/tr>\n
56<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 3<\/td>\n <\/tr>\n
57<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Adrenoleukodystrophy<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 7<\/td>\n <\/tr>\n
58<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Adrenoleukodystrophy<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 7<\/td>\n <\/tr>\n
59<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Adrenoleukodystrophy<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 9<\/td>\n <\/tr>\n
60<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n B-Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 7<\/td>\n <\/tr>\n
61<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Chronic Granulomatous Disease<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 4<\/td>\n <\/tr>\n
62<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Chronic Granulomatous Disease<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 41<\/td>\n <\/tr>\n
63<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Chronic Lymphocytic Leukemia Richter Transformation<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 55<\/td>\n <\/tr>\n
64<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Chronic Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 67<\/td>\n <\/tr>\n
65<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Chronic Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 12<\/td>\n <\/tr>\n
66<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Diffuse Large B-Cell Lymphoma<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 61<\/td>\n <\/tr>\n
67<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Genetically Determined Thrombocytopenia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 4<\/td>\n <\/tr>\n
68<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n High Risk Acute Myeloid Leukaemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 13<\/td>\n <\/tr>\n
69<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Hodgkin Lymphoma<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 32<\/td>\n <\/tr>\n
70<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Inherited Metabolic Disease<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 11<\/td>\n <\/tr>\n
71<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Mds-Rcc Relapse<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 14<\/td>\n <\/tr>\n
72<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Mixed Cellularity\u00a0Hodgkin Lymphoma<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 43<\/td>\n <\/tr>\n
73<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 14<\/td>\n <\/tr>\n
74<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 8<\/td>\n <\/tr>\n
75<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 14<\/td>\n <\/tr>\n
76<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 67<\/td>\n <\/tr>\n
77<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Myelodysplastic Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 9<\/td>\n <\/tr>\n
78<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Osteopetrosis type B<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 13<\/td>\n <\/tr>\n
79<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Other Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 9<\/td>\n <\/tr>\n
80<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Primary Immunodeficiency<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 7<\/td>\n <\/tr>\n
81<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Primary Immunodeficiency Xlp-1<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 18<\/td>\n <\/tr>\n
82<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Relapse T-Acute Lymphoblastic Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 12<\/td>\n <\/tr>\n
83<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Secondary Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 4<\/td>\n <\/tr>\n
84<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Secondary Acute Myelogenous Leukemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 15<\/td>\n <\/tr>\n
85<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 7<\/td>\n <\/tr>\n
86<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 3<\/td>\n <\/tr>\n
87<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 10<\/td>\n <\/tr>\n
88<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 21<\/td>\n <\/tr>\n
89<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 18<\/td>\n <\/tr>\n
90<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 49<\/td>\n <\/tr>\n
91<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 16<\/td>\n <\/tr>\n
92<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 24<\/td>\n <\/tr>\n
93<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 13<\/td>\n <\/tr>\n
94<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 14<\/td>\n <\/tr>\n
95<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 21<\/td>\n <\/tr>\n
96<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Aplastic Anemia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 7<\/td>\n <\/tr>\n
97<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Combined Immunodeficiency<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 2<\/td>\n <\/tr>\n
98<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Severe Congenital Neutropenia<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 1<\/td>\n <\/tr>\n
99<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Shwachman-Diamond Syndrome<\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 10<\/td>\n <\/tr>\n
100<\/td>\n Bone Marrow<\/td>\n Allogeneic<\/td>\n Sickle Cell Disease <\/td>\n Hematology<\/td>\n 2024<\/td>\n Standard Therapy<\/td>\n Poland<\/td>\n 9<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n